Fred Hutchinson Cancer Research Center;Seattle Children's Hospital d/b/a Seattle Children's Research Institute
发明人:
Jensen, Michael,Riddell, Stanley R.,Hudecek, Michael
申请号：
AU2018204209
公开号：
AU2018204209A1
申请日:
2018.06.13
申请国别(地区):
AU
年份:
2018
代理人:
摘要：
#$%^&*AU2018204209A120180705.pdf#####1002206528 ABSTRACT The present invention provides nucleic acids, vectors, host cells, methods and compositions to confer and/or augment immune responses mediated by cellular immunotherapy, such as by adoptively transferring CD8+ central memory T cells or combinations of central memory T cells with CD4+ T cells 5 that are genetically modified to express a chimeric receptor. In embodiments the genetically modified host cell comprises a nucleic acid comprising a polynucleotide coding for a ligand binding domain, a polynucleotide comprising a customized spacer region, a polynucleotide comprising a transmembrane domain, and a polynucleotide comprising an intracellular signaling domain. It has been surprisingly found that the length of the spacer region can affects the ability of chimeric receptor modified T cells to 0 recognize target cells in vitro and affects in vivo efficacy of the chimeric receptor modified T cells. Pharmaceutical formulations produced by the method, and methods of using the same, are also described.
